Gossamer Bio (GOSS) Competitors $1.06 +0.04 (+3.92%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.00 -0.07 (-6.13%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GOSS vs. QURE, ABCL, DAWN, PRAX, CVAC, IMNM, BCAX, REPL, NUVB, and LENZShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include uniQure (QURE), AbCellera Biologics (ABCL), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), CureVac (CVAC), Immunome (IMNM), Bicara Therapeutics (BCAX), Replimune Group (REPL), Nuvation Bio (NUVB), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Gossamer Bio vs. uniQure AbCellera Biologics Day One Biopharmaceuticals Praxis Precision Medicines CureVac Immunome Bicara Therapeutics Replimune Group Nuvation Bio LENZ Therapeutics Gossamer Bio (NASDAQ:GOSS) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, community ranking, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community believe in GOSS or QURE? uniQure received 503 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 70.60% of users gave uniQure an outperform vote while only 66.81% of users gave Gossamer Bio an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15566.81% Underperform Votes7733.19% uniQureOutperform Votes65870.60% Underperform Votes27429.40% Which has higher valuation and earnings, GOSS or QURE? Gossamer Bio has higher revenue and earnings than uniQure. Gossamer Bio is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M2.10-$179.82M-$0.26-4.08uniQure$27.12M29.91-$308.48M-$4.93-3.04 Does the media prefer GOSS or QURE? In the previous week, uniQure had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 4 mentions for uniQure and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.36 beat uniQure's score of 0.43 indicating that Gossamer Bio is being referred to more favorably in the media. Company Overall Sentiment Gossamer Bio Positive uniQure Neutral Do insiders and institutionals believe in GOSS or QURE? 81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 5.0% of Gossamer Bio shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, GOSS or QURE? Gossamer Bio has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, uniQure has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Do analysts prefer GOSS or QURE? Gossamer Bio currently has a consensus price target of $7.50, indicating a potential upside of 607.55%. uniQure has a consensus price target of $38.80, indicating a potential upside of 158.67%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Gossamer Bio is more favorable than uniQure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00uniQure 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Is GOSS or QURE more profitable? Gossamer Bio has a net margin of 0.00% compared to uniQure's net margin of -837.80%. Gossamer Bio's return on equity of -127.28% beat uniQure's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% uniQure -837.80%-188.82%-32.17% SummaryGossamer Bio beats uniQure on 12 of the 19 factors compared between the two stocks. Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$240.85M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.317.3222.5118.54Price / Sales2.10241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book3.796.486.734.25Net Income-$179.82M$143.41M$3.22B$248.18M7 Day Performance10.61%2.58%1.38%1.03%1 Month Performance8.33%5.00%2.79%2.70%1 Year Performance37.43%-3.72%15.41%4.05% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio4.0734 of 5 stars$1.06+3.9%$7.50+607.5%+49.8%$240.85M$114.70M-3.31180Upcoming EarningsNews CoverageQUREuniQure2.5692 of 5 stars$13.57+4.4%$38.80+185.9%+228.2%$733.83M$27.12M-2.74500Upcoming EarningsShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeABCLAbCellera Biologics2.5918 of 5 stars$2.46+1.7%$7.50+204.9%-34.1%$733.05M$28.83M-4.03500Upcoming EarningsGap DownDAWNDay One Biopharmaceuticals2.4635 of 5 stars$7.20+5.3%$32.29+348.4%-56.9%$729.75M$131.16M-6.9960Upcoming EarningsPositive NewsPRAXPraxis Precision Medicines3.4788 of 5 stars$35.90+6.2%$123.33+243.5%-31.0%$723.85M$8.55M-3.49110Analyst ForecastPositive NewsCVACCureVac3.8783 of 5 stars$3.22+3.2%$10.00+210.6%+28.3%$722.37M$535.18M5.85880Analyst ForecastIMNMImmunome2.765 of 5 stars$8.05+1.8%$25.14+212.3%-39.7%$699.96M$9.04M-0.9940News CoveragePositive NewsBCAXBicara TherapeuticsN/A$12.67+4.2%$32.43+156.0%N/A$690.81MN/A0.0032Analyst RevisionNews CoveragePositive NewsGap DownREPLReplimune Group4.2012 of 5 stars$8.82+10.3%$19.43+120.3%+48.8%$679.27MN/A-2.87210Positive NewsNUVBNuvation Bio3.5696 of 5 stars$1.99+1.0%$8.75+339.7%-28.9%$673.97M$7.87M-0.9260Positive NewsLENZLENZ Therapeutics1.9475 of 5 stars$24.44+2.6%$46.60+90.7%+82.7%$673.15MN/A-5.12110News Coverage Related Companies and Tools Related Companies QURE Competitors ABCL Competitors DAWN Competitors PRAX Competitors CVAC Competitors IMNM Competitors BCAX Competitors REPL Competitors NUVB Competitors LENZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOSS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GOSS Stock Free GOSS Stock Alerts